Toggle menu

ENCEPH UK

Start date:
March 2015
End date:
December 2015 (Close to recruitment)
Co-ordinated by:
Brain Infections UK, University of Liverpool
Main trial site:
http://www.encephuk.org/studies

To produce a predictive tool for HSV encephalitis based on the early clinical features, by comparing the clinical features of those with and without HSV encephalitis.

 

Aim

To produce a predictive tool for HSV encephalitis based on the early clinical features, by comparing the clinical features of those with and without HSV encephalitis.

Trial Design

A Prospective multi-centre cohort observational study.

Eligibility criteria (summary of )

Patients who present to the Emergency Department or Acute Medical Unit with suspected encephalitis

Chief Investigator

Professor Tom Solomon

Local PI

Dr Matt Reed

Research Team

EMERGE Research team in collaboration with the Acute Medical Unit (AMU), Critical Care and the Virology team at the RIE

Further information

For more information please refer to main trial website  

Local PI

Dr Matt Reed

Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine

Research Team

Polly Black

Senior Research Nurse

Julia Grahamslaw

Lead Research Nurse

More EMERGE Trials

The Emergency Medicine Annotated Bioresource Consortium (EM-ABC): A pilot and feasability programme

Read more

EMERGE Biobank

Developing a bioresource for all emergency presentations

Strokes caused by a clot are described as ischaemic. When patients experience ischaemic strokes they may be eligible for “clot busting” therapy (thrombolysis). Currently thrombolysis has been shown to improve patient outcome after a stroke if administered within the first 4.5 hours after stroke onset. Up to 25% of patients wake up with symptoms of a stroke. This means they have an unknown onset time for their stroke (so called ‘wake up strokes’). With no known onset time, they are ineligible for thrombolysis. This study will investigate how we might determine stroke onset time.

Read more

MRI in Acute Stroke

The study with PP100-01 in combination with NAC is designed to determine safety and tolerability of PP100-01 when co-administered with NAC as compared to the 12-hr NAC treatment regime for patients that come to the hospital after an overdose of paracetamol/acetaminophen.

Read more

The POP Trial

A Randomised Open Label Exploratory, Safety and Tolerability Study with PP100-01 in Patients Treated with the 12-hour Regimen of N-Acetylcysteine for Paracetamol/Acetaminophen Overdose